Aspen Lung Conference: Bridging the Gap between Innate and Adaptive Immunity in the Lung

阿斯彭肺部会议:弥合肺部先天免疫和适应性免疫之间的差距

基本信息

  • 批准号:
    10469141
  • 负责人:
  • 金额:
    $ 3.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT With an emphasis on the integration of basic, translational, and clinical approaches, the 64th annual Aspen Lung Conference will focus on a central question: how can knowledge of the immunologic mechanisms that underlie lung disease enhance our understanding of disease development and be translated into effective approaches to treat lung disease? To address this central question, the program is organized into a series of thematic sessions, with State of the Art speakers framing the topic. The thematic sessions will focus on (i) the role of innate immunity via mononuclear phagocytes and its impact on inflammatory lung disease, (ii) bridging the gap between the innate and adaptive immune responses in the lung focusing on the host-microbe interactions, (iii) evaluating the interface between the innate and adaptive immune response in COVID and other lung diseases, (iv) the role of adaptive immunity in the development of autoimmunity and autoimmune lung disease, (v) understanding lessons learned from immunologic cancer treatments and approaches, and (vi) defining future treatment options to harness the immune system for generation of novel. By addressing these topics, we seek to accomplish the following: 1) provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding the role of the immune system in the development and progression of chronic lung disease; 2) stimulate interactions between scientific fields to identify emerging and shared interests that may lead to more efficient and productive research; 3) enhance the likelihood of success in translation of preclinical scientific advances into direct patient benefit by developing novel strategies to better understand disease pathogenesis and implement scientific advances in treatment of chronic lung diseases; and 4) challenge and stimulate the scientific interests of trainees and attract a new generation of junior investigators into the field of innate and adaptive immunity in the lung. We have identified 12 outstanding thought leaders to present State of the Art lectures (35 min) on these topics. Each presentation will be followed by 25 minutes of discussion - a hallmark of the Conference. The program continues the Aspen Lung Conference’s dedication to diversity and inclusivity: n=6/13 (54%) of State of the Art speakers/Summarizer are women, and at least 6 of our speakers are from underrepresented racial/ethnic groups. Participation of trainees and junior faculty is facilitated by two 15-minute oral abstracts, selected from submitted abstracts, following each State of the Art speaker (24 total). There will be two evening poster sessions for further presentation opportunities by junior faculty and trainees. The final presentation is provided by a Conference Summarizer, who reviews the impact and common themes of the Conference. The Conference Summary will be published for widespread dissemination, to serve as a “think tank” that not only summarizes the current state of the field, but also identifies key future directions for basic, translation, and clinical research. Finally, and notably, registration for the Aspen Lung Conference is free, encouraging participation from a wide spectrum of trainees and early career investigators.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Janssen其他文献

William Janssen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Janssen', 18)}}的其他基金

Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
  • 批准号:
    10335239
  • 财政年份:
    2018
  • 资助金额:
    $ 3.3万
  • 项目类别:
Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
  • 批准号:
    10225232
  • 财政年份:
    2018
  • 资助金额:
    $ 3.3万
  • 项目类别:
Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
  • 批准号:
    10553701
  • 财政年份:
    2018
  • 资助金额:
    $ 3.3万
  • 项目类别:
Lung Macrophage Programming in Acute Lung Injury
急性肺损伤中的肺巨噬细胞编程
  • 批准号:
    10094076
  • 财政年份:
    2018
  • 资助金额:
    $ 3.3万
  • 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
  • 批准号:
    8528053
  • 财政年份:
    2012
  • 资助金额:
    $ 3.3万
  • 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
  • 批准号:
    8460822
  • 财政年份:
    2012
  • 资助金额:
    $ 3.3万
  • 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
  • 批准号:
    8297328
  • 财政年份:
    2012
  • 资助金额:
    $ 3.3万
  • 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
  • 批准号:
    8661268
  • 财政年份:
    2012
  • 资助金额:
    $ 3.3万
  • 项目类别:
Hif-1 alpha metabolically reprograms recruited alveolar macrophages to promote lung repair
Hif-1 α 通过代谢重新编程招募的肺泡巨噬细胞以促进肺修复
  • 批准号:
    9309186
  • 财政年份:
    2012
  • 资助金额:
    $ 3.3万
  • 项目类别:
Macrophage Apoptosis in Resolution of Acute Lung Injury
巨噬细胞凋亡在缓解急性肺损伤中的作用
  • 批准号:
    9043930
  • 财政年份:
    2012
  • 资助金额:
    $ 3.3万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Characterization of the T cell populations that regulate autoimmunity in asymptomatic anti-nuclear positive individuals and how they become altered in early untreated systemic autoimmune rheumatic disease
无症状抗核阳性个体中调节自身免疫的 T 细胞群的特征及其在早期未经治疗的系统性自身免疫性风湿病中的变化
  • 批准号:
    490019
  • 财政年份:
    2023
  • 资助金额:
    $ 3.3万
  • 项目类别:
    Operating Grants
Environmental Influences Driving Autoimmunity and Autoimmune Disease in Tribal Members
环境影响导致部落成员发生自身免疫和自身免疫疾病
  • 批准号:
    10438444
  • 财政年份:
    2022
  • 资助金额:
    $ 3.3万
  • 项目类别:
Environmental Influences Driving Autoimmunity and Autoimmune Disease in Tribal Members
环境影响导致部落成员发生自身免疫和自身免疫疾病
  • 批准号:
    10707068
  • 财政年份:
    2022
  • 资助金额:
    $ 3.3万
  • 项目类别:
Molecular Mechanism of Autoimmune Germinal Center Reaction and a New Therapeutic Strategy for Autoimmunity
自身免疫生发中心反应的分子机制及自身免疫的新治疗策略
  • 批准号:
    18K19648
  • 财政年份:
    2018
  • 资助金额:
    $ 3.3万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Analysis of autoimmunity caused by environmental factors~New pathogenesis of autoimmune disease~
环境因素引起的自身免疫分析~自身免疫性疾病新发病机制~
  • 批准号:
    16H02690
  • 财政年份:
    2016
  • 资助金额:
    $ 3.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Regulation of autoimmunity in NODRhebmice that represent increase of mTOR-dependent pancreatic βーcells and acceleration of autoimmune destruction.
NODRhebmice 中自身免疫的调节,代表 mTOR 依赖性胰腺 β 细胞的增加和自身免疫破坏的加速。
  • 批准号:
    23890114
  • 财政年份:
    2011
  • 资助金额:
    $ 3.3万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Autoimmune Polyendocrine Syndrome Type 1 - A rare disorder of childhood as a model of autoimmunity
1 型自身免疫性多内分泌综合症 - 一种罕见的儿童期疾病,是自身免疫的模型
  • 批准号:
    nhmrc : 410230
  • 财政年份:
    2007
  • 资助金额:
    $ 3.3万
  • 项目类别:
    NHMRC Strategic Awards
Investigation of mechanisms by which BTLA inhibit autoimmunity and its application for the treatment of autoimmune diseases
BTLA抑制自身免疫的机制研究及其在自身免疫性疾病治疗中的应用
  • 批准号:
    19591155
  • 财政年份:
    2007
  • 资助金额:
    $ 3.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AUTOIMMUNITY TO PROTEOGLYCANS IN AUTOIMMUNE DISEASE
自身免疫性疾病中对蛋白聚糖的自身免疫
  • 批准号:
    3791062
  • 财政年份:
  • 资助金额:
    $ 3.3万
  • 项目类别:
AUTOIMMUNITY TO PROTEOGLYCANS IN AUTOIMMUNE DISEASE
自身免疫性疾病中对蛋白聚糖的自身免疫
  • 批准号:
    3769002
  • 财政年份:
  • 资助金额:
    $ 3.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了